## Go back to RMG website



Basic overview, dg. MGUS
No. of diagnosed patients in years $(N=3172)$


| Year of diagnosis | Males [ N ] | Males [\%] | Females [ N ] | Females [\%] | Total [ N$]$ | Total [\%] | Sex | Number of patients | [\%] |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| <2000 | 50 | 3.5 | 84 | 4.9 | 134 | 4.2 | Males | 1442 | 45.5 |
| 2000 | 15 | 1.0 | 24 | 1.4 | 39 | 1.2 | Females | 1730 | 54.5 |
| 2001 | 13 | 0.9 | 29 | 1.7 | 42 | 1.3 |  |  |  |
| 2002 | 25 | 1.7 | 30 | 1.7 | 55 | 1.7 |  |  |  |
| 2003 | 34 | 2.4 | 46 | 2.7 | 80 | 2.5 |  |  |  |
| 2004 | 44 | 3.1 | 54 | 3.1 | 98 | 3.1 |  |  |  |
| 2005 | 44 | 3.1 | 64 | 3.7 | 108 | 3.4 |  |  |  |
| 2006 | 52 | 3.6 | 56 | 3.2 | 108 | 3.4 |  |  |  |
| 2007 | 83 | 5.8 | 110 | 6.4 | 193 | 6.1 |  |  |  |
| 2008 | 92 | 6.4 | 130 | 7.5 | 222 | 7.0 |  |  |  |
| 2009 | 128 | 8.9 | 160 | 9.2 | 288 | 9.1 |  |  |  |
| 2010 | 142 | 9.8 | 168 | 9.7 | 310 | 9.8 |  |  |  |
| 2011 | 153 | 10.6 | 126 | 7.3 | 279 | 8.8 |  |  |  |
| 2012 | 100 | 6.9 | 138 | 8.0 | 238 | 7.5 |  |  |  |
| 2013 | 106 | 7.4 | 114 | 6.6 | 220 | 6.9 |  |  |  |
| 2014 | 106 | 7.4 | 113 | 6.5 | 219 | 6.9 |  |  |  |
| 2015 | 120 | 8.3 | 136 | 7.9 | 256 | 8.1 |  |  |  |
| 2016 | 117 | 8.1 | 122 | 7.1 | 239 | 7.5 |  |  |  |
| 2017 | 18 | 1.2 | 26 | 1.5 | 44 | 1.4 |  |  |  |

Fig. 2. Publicly available visualisation of data from the registry.

## 1. Go to browser

https://rmg.healthregistry.org/index.php?pg=data
Homepage Participating centres Patients Guarantors Consent Interactive browser Publications Technology

## Registry Visualization

Please choose from the options bellow to enter either registry visualization for general public or authenticated detailed site-specific visualization.


Fig. 3A. Authenticated visualisation - login and data selection.

## 3. Main page

## Reports

Download report(s) in PDF format

| ID | Centre | State [refresh] | Result | Created | Last modified | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 19 | All CZ centres | new |  | 25.5.2017, 16:03 | 25.5.2017, 16:03 | $\bigcirc$ |
| 18 | All CZ centres | finished | PDF | 25.5.2017, 14:02 | 25.5.2017, 14:10 | $\frac{1}{1}$ |
| 17 | All CZ centres | finished | PDF | 25.5.2017, 12:59 | 25.5.2017, 13:05 | แ |
| 16 | All centres | finished | PDF | 25.5.2017, 12:15 | 25.5.2017, 12:25 | 0 |
| 15 | All centres | finished | PDF | 24.5.2017, 17:25 | 24.5.2017, 17:35 | - |

All cz centres
Year of treatment initiation: 2010-2017
Age (treatment initiation): total
Line of treatment: 2 nd line, 3rd line
Clinical trial: total
Autologous stem cell transplantation (Asct): total
Treatment regimen: total
Patients: 1884 , treatment lines: 2751 (Caution: Analytical outputs display nonval
I. Summary lists
I.1 Numbers of diagnosed patients in time
I.2 Number of initiated treatments in time
I. 3 Year of last evaluation of patients alive with known status
II. Basic overview - patients
II. 1 Sex
II. 2 Age (at diagnosis)
II. 3 Follow up from diagnosis (years)
II. 4 ISS classification
II. 5 Performance status
III. Basic overview - treatment lines
III. 1 Sex
III. 2 Age (treatment initiation)
III. 3 Follow up from treatment beginning (months)
III. 4 ISS classification at treatment initiation
III. 5 Performance status at treatment initiation
III. 6 Line of treatment
III. 7 Treatment regimen
III. 8 Autologous stem cell transplantation
III. 9 Clinical trial
IV. Final treatment response and toxicity
IV. 1 Treatment termination
IV. 2 Treatment response
IV. 3 Any toxicity during treatment
IV. 4 Toxicity during treatment

## V. Patient survival

V. 1 Total
V. 2 Age (treatment initiation)
V. 3 ISS classification at treatment initiation
V. 4 Performance status at treatment initiation
V. 5 Line of treatment
V. 6 Autologous stem cell transplantation
V. 7 M-protein type
V. 8 Light chain type
V. 9 IGH disruption
V. $10 \mathrm{t}(11 ; 14)$
V. $11 \mathrm{t}(4 ; 14)$
V. $12 \mathrm{t}(14 ; 16)$
V. 13 del(13)(q14)/monosomy 13
V. 14 gain 1q21
V. 15 del(17)(p13)
V. 16 Hyperdiploidy
V. 17 LDH (ukat/l)
V. 18 Creatinine level (umol/l)
V. 19 Beta2 microglobulin (mg/l)
V. 20 CRP (mg/l)

Fig. 3B. Authenticated visualisation - interface for downloading PDF reports (upper part) and the main menu to display individual components (lower part).


Fig. 3C. Authenticated visualisation - an example of outputs.

